OA12370A - Pharmaceutical formulation of salmeterol and fluticazone propionate. - Google Patents

Pharmaceutical formulation of salmeterol and fluticazone propionate. Download PDF

Info

Publication number: OA12370A
Authority: OA; OAPI
Prior art keywords: salmeterol; sait; copd; pharmaceutical formulation; treatment
Prior art date: 2000-08-31

Application number

OA1200300054A

Other languages

English (en)

Inventor

Donald Herbert Horstman

Claire Julia Maden

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-31

Filing date

2001-08-31

Publication date

2004-03-19

2001-08-31 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2004-03-19 Publication of OA12370A publication Critical patent/OA12370A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title claims description 6
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 title description 20
229960004017 salmeterol Drugs 0.000 title description 19
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 title description 8
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 20
WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims abstract description 16
239000000203 mixture Substances 0.000 claims description 18
229960000289 fluticasone propionate Drugs 0.000 claims description 14
238000009472 formulation Methods 0.000 claims description 13
229950000339 xinafoate Drugs 0.000 claims description 11
239000003814 drug Substances 0.000 claims description 3
229940124597 therapeutic agent Drugs 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
238000002560 therapeutic procedure Methods 0.000 claims 1
229940021597 salmeterol and fluticasone Drugs 0.000 abstract description 4
208000000059 Dyspnea Diseases 0.000 description 6
206010013975 Dyspnoeas Diseases 0.000 description 6
230000003862 health status Effects 0.000 description 4
230000000241 respiratory effect Effects 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
208000006673 asthma Diseases 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000008101 lactose Substances 0.000 description 3
238000000034 method Methods 0.000 description 3
229940124624 oral corticosteroid Drugs 0.000 description 3
239000000902 placebo Substances 0.000 description 3
229940068196 placebo Drugs 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 2
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
208000037656 Respiratory Sounds Diseases 0.000 description 2
206010047924 Wheezing Diseases 0.000 description 2
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
239000013066 combination product Substances 0.000 description 2
229940127555 combination product Drugs 0.000 description 2
230000005713 exacerbation Effects 0.000 description 2
230000004199 lung function Effects 0.000 description 2
239000003380 propellant Substances 0.000 description 2
229960002052 salbutamol Drugs 0.000 description 2
239000007921 spray Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000011623 Obstructive Lung disease Diseases 0.000 description 1
208000027771 Obstructive airways disease Diseases 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000048 adrenergic agonist Substances 0.000 description 1
239000003513 alkali Substances 0.000 description 1
230000007815 allergy Effects 0.000 description 1
150000001398 aluminium Chemical class 0.000 description 1
239000005030 aluminium foil Substances 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
229940124748 beta 2 agonist Drugs 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
229940124446 critical care medicine Drugs 0.000 description 1
229940109248 cromoglycate Drugs 0.000 description 1
IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229940112141 dry powder inhaler Drugs 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
229960001888 ipratropium Drugs 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
229960004398 nedocromil Drugs 0.000 description 1
NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
229960000797 oxitropium Drugs 0.000 description 1
208000037821 progressive disease Diseases 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
229960005018 salmeterol xinafoate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 1
229940110309 tiotropium Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Otolaryngology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Treatment Of Water By Ion Exchange (AREA)

OA1200300054A 2000-08-31 2001-08-31 Pharmaceutical formulation of salmeterol and fluticazone propionate. OA12370A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US22938100P	2000-08-31	2000-08-31

Publications (1)

Publication Number	Publication Date
OA12370A true OA12370A (en)	2004-03-19

Family

ID=22860986

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200300054A OA12370A (en)	2000-08-31	2001-08-31	Pharmaceutical formulation of salmeterol and fluticazone propionate.

Country Status (24)

Country	Link
US (1)	US20040009963A1 (es)
EP (1)	EP1313484A2 (es)
JP (1)	JP2004507494A (es)
KR (1)	KR20030031997A (es)
CN (1)	CN1449288A (es)
AP (1)	AP2003002753A0 (es)
AR (1)	AR030516A1 (es)
AU (1)	AU2001284236A1 (es)
BG (1)	BG107596A (es)
BR (1)	BR0113555A (es)
CA (1)	CA2420532A1 (es)
EA (1)	EA200300152A1 (es)
EC (1)	ECSP034487A (es)
HU (1)	HUP0303755A2 (es)
IL (1)	IL154403A0 (es)
MA (1)	MA25834A1 (es)
MX (1)	MXPA03001752A (es)
NO (1)	NO20030899L (es)
OA (1)	OA12370A (es)
PE (1)	PE20020387A1 (es)
PL (1)	PL365582A1 (es)
SK (1)	SK2302003A3 (es)
WO (1)	WO2002017894A2 (es)
ZA (1)	ZA200301475B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0106031D0 (en) *	2001-03-12	2001-05-02	Glaxo Group Ltd	Use
AU2003263717A1 (en) *	2002-09-25	2004-04-19	Astrazeneca Ab	A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
WO2005013963A1 (en) *	2003-08-06	2005-02-17	Galephar M/F	Advantageous combinations for inhalation of nacystelyn and bronchodilators
TR200907913A2 (tr) *	2009-10-20	2011-05-23	Bi̇lgi̇ç Mahmut	İnhalason yolu ile alınmak üzere kuru toz formunda farmasötik bileşim
TR200909791A2 (tr) *	2009-12-25	2011-07-21	B�Lg�� Mahmut	Salmeterol ve flutikazon içeren farmasötik bileşim@
TR201000681A2 (tr) *	2010-01-29	2011-08-22	B�Lg�� Mahmut	İnhalasyon yoluyla alınan kuru toz formülasyonları.
US8834931B2 (en)	2009-12-25	2014-09-16	Mahmut Bilgic	Dry powder formulation containing tiotropium for inhalation
US20150224197A1 (en) *	2012-07-05	2015-08-13	Arven Ilac Sanayi Ve Ticaret A.S.	Inhalation compositions
US10111957B2 (en)	2012-07-05	2018-10-30	Arven Ilac Snayi ve Ticaret A.S.	Inhalation compositions comprising glucose anhydrous
WO2014007771A2 (en)	2012-07-05	2014-01-09	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Inhalation compositions comprising muscarinic receptor antagonist
AU2014261538A1 (en) *	2013-04-29	2015-12-10	Sanofi Sa	Inhalable pharmaceutical compositions and the inhaler devices containing them
MA41378A (fr) *	2015-01-20	2017-11-28	Teva Branded Pharmaceutical Prod R & D Inc	Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
GB202202297D0 (en)	2022-02-21	2022-04-06	Verona Pharma Plc	Formulation production process
CN119816309A (zh) *	2022-08-08	2025-04-11	维罗纳制药公司	用于治疗中度慢性阻塞性肺病(copd)的恩塞芬汀(rpl-554)
TW202506117A (zh)	2023-06-26	2025-02-16	英商維羅納製藥Ｐｌｃ公司	顆粒組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL104068A (en) *	1991-12-12	1998-10-30	Glaxo Group Ltd	Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9808802D0 (en) *	1998-04-24	1998-06-24	Glaxo Group Ltd	Pharmaceutical formulations
GB9924992D0 (en) *	1999-10-21	1999-12-22	Glaxo Group Ltd	Pharmaceutical aerosol formulations
WO2001047493A1 (en) *	1999-12-24	2001-07-05	Glaxo Group Limited	Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate

2001
- 2001-08-29 PE PE2001000867A patent/PE20020387A1/es not_active Application Discontinuation
- 2001-08-29 AR ARP010104122A patent/AR030516A1/es unknown
- 2001-08-31 CA CA002420532A patent/CA2420532A1/en not_active Abandoned
- 2001-08-31 AP APAP/P/2003/002753A patent/AP2003002753A0/en unknown
- 2001-08-31 HU HU0303755A patent/HUP0303755A2/hu unknown
- 2001-08-31 KR KR10-2003-7002890A patent/KR20030031997A/ko not_active Withdrawn
- 2001-08-31 SK SK230-2003A patent/SK2302003A3/sk unknown
- 2001-08-31 BR BR0113555-4A patent/BR0113555A/pt not_active Application Discontinuation
- 2001-08-31 MX MXPA03001752A patent/MXPA03001752A/es unknown
- 2001-08-31 JP JP2002522868A patent/JP2004507494A/ja active Pending
- 2001-08-31 WO PCT/GB2001/003928 patent/WO2002017894A2/en not_active Ceased
- 2001-08-31 AU AU2001284236A patent/AU2001284236A1/en not_active Abandoned
- 2001-08-31 IL IL15440301A patent/IL154403A0/xx unknown
- 2001-08-31 EA EA200300152A patent/EA200300152A1/ru unknown
- 2001-08-31 CN CN01814708A patent/CN1449288A/zh active Pending
- 2001-08-31 US US10/363,438 patent/US20040009963A1/en not_active Abandoned
- 2001-08-31 PL PL01365582A patent/PL365582A1/xx not_active Application Discontinuation
- 2001-08-31 OA OA1200300054A patent/OA12370A/en unknown
- 2001-08-31 EP EP01963205A patent/EP1313484A2/en not_active Withdrawn
2003
- 2003-02-20 EC EC2003004487A patent/ECSP034487A/es unknown
- 2003-02-24 ZA ZA200301475A patent/ZA200301475B/en unknown
- 2003-02-26 NO NO20030899A patent/NO20030899L/no not_active Application Discontinuation
- 2003-02-27 BG BG107596A patent/BG107596A/bg unknown
- 2003-02-27 MA MA27058A patent/MA25834A1/fr unknown

Also Published As

Publication number	Publication date
NO20030899L (no)	2003-04-28
AP2003002753A0 (en)	2003-06-30
BG107596A (bg)	2004-01-30
US20040009963A1 (en)	2004-01-15
IL154403A0 (en)	2003-09-17
AU2001284236A1 (en)	2002-03-13
KR20030031997A (ko)	2003-04-23
AR030516A1 (es)	2003-08-20
BR0113555A (pt)	2003-07-22
PL365582A1 (en)	2005-01-10
SK2302003A3 (en)	2003-08-05
JP2004507494A (ja)	2004-03-11
ZA200301475B (en)	2004-05-24
EA200300152A1 (ru)	2003-08-28
MA25834A1 (fr)	2003-07-01
CA2420532A1 (en)	2002-03-07
CN1449288A (zh)	2003-10-15
WO2002017894A2 (en)	2002-03-07
MXPA03001752A (es)	2003-06-04
EP1313484A2 (en)	2003-05-28
HUP0303755A2 (hu)	2004-04-28
ECSP034487A (es)	2003-03-31
NO20030899D0 (no)	2003-02-26
PE20020387A1 (es)	2002-06-24
WO2002017894A3 (en)	2002-08-08

Publication	Publication Date	Title
KR100234864B1 (ko)	1999-12-15	기도 및 폐질환을 치료하기 위한 모메타손푸로에이트 약제
WO2001078745A1 (en)	2001-10-25	Medical combinations comprising formoterol and fluticasone proprionate
US20030119859A1 (en)	2003-06-26	Medical combinations comprising tiotropium and rofleponide
US20030109510A1 (en)	2003-06-12	Medical combinations comprising formoterol and budesonide
JP2004538241A (ja)	2004-12-24	チオトロピウムとプロピオン酸フルチカゾンを含む組合せ医薬
OA12370A (en)	2004-03-19	Pharmaceutical formulation of salmeterol and fluticazone propionate.
AU2002334126B2 (en)	2005-12-15	Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma
AU2002334126A1 (en)	2003-07-03	Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma
US20030114537A1 (en)	2003-06-19	Medical combinations comprising mometasone and salmeterol
WO2001078744A1 (en)	2001-10-25	Medical combinations comprising formoterol and mometasone
EP1274436A1 (en)	2003-01-15	Medical compositions comprising (r,r)-formoterol und rofleponide
US20030096874A1 (en)	2003-05-22	Respiratory compositions
US20040019025A1 (en)	2004-01-29	Medical compositions comprising (r,r)-formoterol and rofleponide
HK1232788A1 (en)	2018-01-19	Combinations of tiotropium bromide, formoterol and budesonide for the treatment of copd